Treatments of MODY3 are primarily sulfonylureas and secondarily insulins, glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors, while the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is rather unexplored
It helps inhibit the production of melanin, the pigment responsible for dark spots and uneven skin tone, resulting in a more radiant and even appearance
Serious adverse events were reported in 15% of patients
therapeutic studies use up to 3,000 mg (NIH)
A 2025 retrospective cohort study of 210 T2DM patients on oral semaglutide for 18 months found no significant association between rs6923761 or rs761387 genotypes and changes in HbA1c or BMI in that relatively well-controlled population (Candido et al., 2025) suggesting that receptor-level genotype effects may be detectable primarily in subpopulations with higher pharmacological demand or larger baseline disease severity, rather than as universal predictors
While this helps patients eat less and lose fat, chronic calorie or protein restriction can have unintended effects on key hormones: Lower caloric intake Lower insulin levels
